Search details
1.
Interferon signature guiding therapeutic decision making: ruxolitinib as first-line therapy for severe juvenile dermatomyositis?
Rheumatology (Oxford)
; 60(4): e136-e138, 2021 04 06.
Article
in English
| MEDLINE | ID: mdl-33200187
Results
1 -
1
de 1
1
Next >
>>